92161
document
Zolmitriptan ( 311C90 ) does not interact with fluoxetine in healthy volunteers . Zolmitriptan ( Zomig , formerly 311C90 ) is a selective 5-hydroxytryptamine ( 5-HT ) 1B/1D-receptor agonist with central and peripheral activity for the acute treatment of migraine . This randomized , placebo-controlled , crossover study investigated the effects of fluoxetine administration on the pharmacokinetics and pharmacodynamics of zolmitriptan . Twenty volunteers were given single doses of fluoxetine 20 mg or an identical placebo daily for 28 days prior to receiving a single 10 mg oral dose of zolmitriptan . Sixteen volunteers completed the two treatment phases . The pharmacokinetic parameters of zolmitriptan and its metabolites were not significantly affected by fluoxetine pretreatment . The pharmacodynamic effects of zolmitriptan were also unaffected by fluoxetine pretreatment . There were small , clinically insignificant increases in blood pressure following zolmitriptan which were unaltered by fluoxetine . Zolmitriptan was well tolerated when given alone or concomitantly with fluoxetine . These results indicate that there is no contraindication to the use of zolmitriptan in patients treated concurrently with selective serotonin reuptake inhibitors and that no adjustment of the zolmitriptan dose is required in these circumstances .
92162
Intervention_Pharmacological
Zolmitriptan ( 311C90 )
92163
Intervention_Pharmacological
fluoxetine
92164
Intervention_Pharmacological
Zolmitriptan ( Zomig , formerly 311C90 )
92165
Intervention_Pharmacological
selective 5-hydroxytryptamine ( 5-HT ) 1B/1D-receptor agonist
92166
Intervention_Control
placebo-controlled
92167
Intervention_Pharmacological
fluoxetine
92168
Intervention_Pharmacological
zolmitriptan
92169
Intervention_Pharmacological
fluoxetine 20 mg
92170
Intervention_Control
placebo
92171
Intervention_Pharmacological
zolmitriptan
92172
Intervention_Pharmacological
zolmitriptan
92173
Intervention_Pharmacological
fluoxetine
92174
Intervention_Pharmacological
zolmitriptan
92175
Intervention_Pharmacological
fluoxetine
92176
Intervention_Pharmacological
zolmitriptan
92177
Intervention_Pharmacological
fluoxetine
92178
Intervention_Pharmacological
Zolmitriptan
92179
Intervention_Pharmacological
fluoxetine
92180
Intervention_Pharmacological
zolmitriptan
92181
Intervention_Pharmacological
selective serotonin reuptake inhibitors
92182
Intervention_Pharmacological
zolmitriptan
92183
Outcome_Other
pharmacokinetics and pharmacodynamics of zolmitriptan
92184
Outcome_Other
pharmacokinetic parameters of zolmitriptan and its metabolites
92185
Outcome_Other
pharmacodynamic effects of zolmitriptan
92186
Outcome_Physical
blood pressure
92187
Outcome_Other
well tolerated
92188
Outcome_Other
contraindication
92189
Participant_Sample-size
Twenty
92190
Participant_Sample-size
Sixteen
92191
Participant_Condition
serotonin reuptake inhibitors